Q-omics provides the consensus-scored SRSF7 profile across patient tissues and cancer cell-line models. SRSF7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SRSF7 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SRSF7 protein abundance shows 32,705 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where SRSF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRSF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRSF7 survival associations across molecular data types. SRSF7 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRSF7 RNA expression–survival associations across cancer types. High SRSF7 expression shows unfavorable associations in ACC, UVM, KIRC, KIRP, LIHC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SRSF7 RNA expression.
This table summarizes SRSF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SRSF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRSF7 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, HNSC, LIHC and STAD. The COAD box plot shows higher SRSF7 RNA expression in tumor versus normal tissue (log2 FC = +1.237, t-test p < 0.001).
This table shows molecular features associated with SRSF7 in patient tissues and cancer cell lines. In patient samples, SRSF7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SRSF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
